| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -71.2 | -36.3 |
| Net income | -71.2 | -36.3 |
| EPS (diluted, $ a share) | $-1.04 | $-0.67 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: BCAX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bicara Therapeutics Inc.: key numbers
- Share price
- $9.60Close, Nov 17
- Market cap
- $637M
- Shares outstanding
- 66.39MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bicara Therapeutics Inc.
All →Bicara Therapeutics Financial Results
Bicara Therapeutics reported Q3 2026 financial results, ending the period with $442.3 million in cash and marketable securities. The company achieved substantial enrollment in its FORTIFI-HN01 pivotal trial for head and neck cancer, with topline interim results expected in mid-2027. Management expects current cash reserves to fund operations into the first half of 2029.
- Term
- Q3 2026
“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
“Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer